Literature DB >> 8634618

What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.

D Wonderling1, S Langham, M Buxton, C Normand, C McDermott.   

Abstract

OBJECTIVES: To provide a commentary on the economic evaluations of the Oxcheck and British family heart studies: direct comparison of their relative effectiveness and cost effectiveness; comparisons with other interventions; and consideration of problems encountered.
DESIGN: Modelling from cost and effectiveness data to estimate of cost per life year gained.
SUBJECTS: Middle aged men and women.
INTERVENTIONS: Screening for cardiovascular risk factors followed by appropriate lifestyle advice and drug intervention in general practice, and other primary coronary risk management strategies. MAIN OUTCOME MEASURES: Life years gained; cost per life year gained.
RESULTS: Depending on the assumed duration of risk reduction, the programme cost per discounted life year gained ranged from 34,800 pounds for a 1 year duration to 1500 pounds for 20 years for the British family heart study and from 29,300 pounds to 900 pounds for Oxcheck. These figures exclude broader net clinical and cost effects and longer term clinical and cost effects other than coronary mortality.
CONCLUSIONS: Despite differences in underlying methods, the estimates in the two economic analyses of the studies can be directly compared. Neither study was large enough to provide precise estimates of the overall net cost. Modelling to cost per life year gained provides more readily interpretable measures. These estimates emphasise the importance of the relatively weak evidence on duration effect. Only if the effect lasts at least five years is the Oxcheck programme likely to be cost effective. The effect must last for about 10 years to justify the extra cost associated with the British family heart study.

Entities:  

Mesh:

Year:  1996        PMID: 8634618      PMCID: PMC2351093          DOI: 10.1136/bmj.312.7041.1274

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  11 in total

1.  Discounting and health benefits.

Authors:  M Parsonage; H Neuburger
Journal:  Health Econ       Date:  1992-04       Impact factor: 3.046

2.  Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977.

Authors:  A Nissinen; J Tuomilehto; T E Kottke; P Puska
Journal:  Med Care       Date:  1986-08       Impact factor: 2.983

3.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?

Authors:  I S Kristiansen; A E Eggen; D S Thelle
Journal:  BMJ       Date:  1991-05-11

4.  Cost-effectiveness of interventions to prevent or treat coronary heart disease.

Authors:  M C Weinstein; W B Stason
Journal:  Annu Rev Public Health       Date:  1985       Impact factor: 21.981

5.  Some guidelines on the use of cost effectiveness league tables.

Authors:  J Mason; M Drummond; G Torrance
Journal:  BMJ       Date:  1993-02-27

6.  Screening for cardiovascular risk in general practice.

Authors:  N Stott
Journal:  BMJ       Date:  1994-01-29

7.  The Dundee coronary risk-disk for management of change in risk factors.

Authors:  H Tunstall-Pedoe
Journal:  BMJ       Date:  1991-09-28

8.  Selection of end points in economic evaluations of coronary-heart-disease interventions.

Authors:  M F Drummond; J Heyse; J Cook; A McGuire
Journal:  Med Decis Making       Date:  1993 Jul-Sep       Impact factor: 2.583

9.  Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study.

Authors:  S Langham; M Thorogood; C Normand; J Muir; L Jones; G Fowler
Journal:  BMJ       Date:  1996-05-18

10.  Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study.

Authors:  D Wonderling; C McDermott; M Buxton; A L Kinmonth; S Pyke; S Thompson; D Wood
Journal:  BMJ       Date:  1996-05-18
View more
  24 in total

1.  Can dietary assessment in general practice target patients with unhealthy diets?

Authors:  P Little; J Barnett; A L Kinmonth; B Margetts; J Gabbay; R Thompson; D Warm; S Wooton
Journal:  Br J Gen Pract       Date:  2000-01       Impact factor: 5.386

2.  Is population coronary heart disease risk screening justified? A discussion of the National Service Framework for coronary heart disease (Standard 4).

Authors:  A Rouse; P Adab
Journal:  Br J Gen Pract       Date:  2001-10       Impact factor: 5.386

3.  Preventing cardiovascular disease in primary care.

Authors:  L Toop; D Richards
Journal:  BMJ       Date:  2001-08-04

4.  Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial.

Authors:  James P Raftery; Guiqing L Yao; Peter Murchie; Neil C Campbell; Lewis D Ritchie
Journal:  BMJ       Date:  2005-02-16

5.  Rationing health care: moving the debate forward.

Authors:  R Smith
Journal:  BMJ       Date:  1996-06-22

6.  Barriers to evidence based policy.

Authors:  D Florin
Journal:  BMJ       Date:  1996-10-12

7.  Cost effectiveness of health checks. Effect of intervention was sustained.

Authors:  J Muir; L Jones; G Fowler
Journal:  BMJ       Date:  1996-09-07

8.  Cost effectiveness of health checks. Factoring in effect on mortality from stroke increases cost effectiveness.

Authors:  J Graham
Journal:  BMJ       Date:  1996-09-07

9.  Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs.

Authors:  C Sanderson; M Kubin
Journal:  Health Care Manag Sci       Date:  2001-12

10.  Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA).

Authors:  Nadja Chernyak; Frank Petrak; Kristin Plack; Martin Hautzinger; Matthias J Müller; Guido Giani; Andrea Icks
Journal:  BMC Geriatr       Date:  2009-07-01       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.